Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $4 | $2 | $1 |
| - Cash | $0 | $1 | $1 | $2 |
| + Debt | $0 | $2 | $2 | $2 |
| Enterprise Value | $2 | $5 | $4 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -28.3% | 0% | 87.6% | – |
| Gross Profit | $0 | -$1 | -$1 | -$0 |
| % Margin | 0% | -164.3% | -164.3% | -81.1% |
| EBITDA | -$1 | -$2 | -$1 | -$2 |
| % Margin | -347.5% | -395.7% | -217.6% | -809.2% |
| Net Income | -$2 | -$2 | -$2 | -$2 |
| % Margin | -764.5% | -534.8% | -400.8% | -1,082.5% |
| EPS Diluted | -18,960 | -1.2 | -1.2 | -5.6 |
| % Growth | -1,579,900% | 0% | 78.6% | – |
| Operating Cash Flow | – | -$1 | -$1 | -$1 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | -$1 | -$1 | -$1 |